Paper Details

  1. Home
  2. Paper Details

Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.

Author: AudisioErnesta, BassanRenato, BenciniSara, BonettiMaria Ida, BosiAlberto, CutiniIlaria, FarinaGiorgio, FerreroDario, GianfaldoniGiacomo, GiupponiDamiano, IntermesoliTamara, MannelliFrancesco, MasciulliArianna, PavoniChiara, RambaldiAlessandro, ScattolinAnna Maria

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated whether early changes in the number of blast cells in the blood (peripheral blast cell clearance, PBC) could predict how well patients with acute myeloid leukemia (AML) would respond to chemotherapy. Patients with a higher PBC after 3 days of treatment were more likely to achieve complete remission (CR) and had a better overall outcome. The study also found that PBC was a good predictor of how well patients responded to high-dose chemotherapy. This suggests that measuring PBC early on could help personalize AML treatment and improve patient outcomes.
Paper Details　
Original Abstract of the Article :
Although genetics is a relevant risk factor in acute myeloid leukemia (AML), it can be minimally informative and/or not readily available for the early identification of patients at risk for treatment failure. In a randomized trial comparing standard vs high-dose induction (ClinicalTrials.gov #NCT00...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988394/

データ提供：米国国立医学図書館（NLM）

Early Peripheral Clearance of Leukemia-Associated Immunophenotypes: A New Way to Predict AML Outcomes?

Acute myeloid leukemia (AML) is a complex and often aggressive cancer of the blood and bone marrow. This study explores the potential of early peripheral blast cell clearance (PBC) as a rapid predictor of chemotherapy response in AML patients. The authors analyzed data from a randomized trial comparing standard vs high-dose induction chemotherapy, focusing on the relationship between PBC and treatment outcomes. Their findings offer valuable insights into the potential of PBC as a predictive biomarker for AML treatment response.

Early Insights into AML Response with Peripheral Blast Cell Clearance

The study revealed a strong correlation between early PBC and the achievement of complete remission (CR) after AML induction therapy. Patients with higher PBC levels were significantly more likely to achieve CR compared to those with lower PBC levels. The study also demonstrated that PBC can predict post-remission outcomes, highlighting its potential as a prognostic factor in AML. This research suggests that PBC could play a crucial role in guiding treatment decisions and improving outcomes for AML patients.

Making Informed Decisions in AML Treatment

The findings of this study provide valuable information for clinicians treating AML patients. The study’s findings suggest that PBC could be a valuable tool for identifying patients at risk for treatment failure and for tailoring treatment strategies accordingly. This could lead to more personalized and effective treatment approaches, ultimately improving outcomes for AML patients. Further research is needed to validate PBC as a predictive biomarker and to explore its potential for guiding treatment decisions in clinical practice.

Dr.Camel's Conclusion

Like a desert oasis that reveals its hidden depths upon closer inspection, PBC offers valuable insights into the complex landscape of AML treatment. This study provides a roadmap for using PBC to predict treatment outcomes and personalize treatment strategies, ultimately leading to better outcomes for AML patients.

Date :
  1. Date Completed 2021-04-14
  2. Date Revised 2021-09-25
Further Info :

Pubmed ID

31978214

DOI: Digital Object Identifier

PMC6988394

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.